Physician profile
William R Kessler
NPI 1114976685
$1,238.89
in general payments reported to CMS, 2019-2025
15 companies · $545 in 2025
The $545 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $39.99 · 2021: $168 · 2022: $33.26 · 2024: $287 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $279.72 | 2019-2025 | Suflave, Sutab |
| Steris Corporation | $247.50 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $151.57 | 2024-2025 | Eohilia, Entyvio |
| Abiomed | $142.89 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $92.35 | 2025 | Voquezna |
| Abbvie INC. | $70.29 | 2024-2025 | |
| Eisai INC. | $51.23 | 2025 | |
| Ardelyx, INC. | $42.77 | 2025 | Ibsrela |
| Janssen Biotech, INC. | $29.68 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $28.53 | 2025 | Dupixent |
| Argenx US, INC. | $26.45 | 2025 | Vyvgart |
| Madrigal Pharmaceuticals | $23.41 | 2025 | Rezdiffra |
| Cycle Pharmaceuticals INC | $20.97 | 2025 | Tascenso Odt |
| Sumitomo Pharma America, INC. | $17.60 | 2025 | Orgovyx |
| Echosens North America, INC. | $13.93 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.